A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (NCT06570798)
A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
🩺 Plain-English Summary (8th-Grade Level)
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research and Innovation Institute — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (58 Sites)
Showing the first 25 of 58 sites.
- HonorHealth Research and Innovation Institute — Scottsdale, Arizona
- University of Colorado — Aurora, Colorado
- Vida Research Center — Hialeah, Florida
- Homestead Associates In Research Inc — Homestead, Florida
- Vitaly Clinical Research — Miami, Florida
- Bioresearch Partner Coral Terrace — South Miami, Florida
- University Medical Center New Orleans — New Orleans, Louisiana
- Massachusetts General Hospital — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Northwell Health — Great Neck, New York
- Westchester Medical Center — Hawthorne, New York
- Columbia University Medical Center — New York, New York
- University of Rochester Medical Center — Rochester, New York
- MetroHealth Medical Center — Cleveland, Ohio
- The Metro Health System Main Campus — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Prolato Clinical Research Center — Houston, Texas
- Seattle Rheumatology Associates — Seattle, Washington
- Linear Clinical Research Limited — Perth, Western Australia
- Cliniques Universtaire Saint Luc Universite Catholique de Louvain — Brussels,
- Universitair Ziekenhuis Gent — Ghent,
- Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven,
- Centre Hospitalier Universitaire de Liege - Sart Tilman — Liège,
- Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre — Le Kremlin-Bicêtre,
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez — Lille,
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.